| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 08/09/2001 | WO2001057002A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | WO2001056993A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056981A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | WO2001056607A1 Integrin expression inhibitors |
| 08/09/2001 | WO2001056598A2 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 08/09/2001 | WO2001056574A1 Use of desloratadine for treating allergic and inflammatory conditions |
| 08/09/2001 | WO2001056556A2 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders |
| 08/09/2001 | WO2001056554A2 Use of retinoid-type compounds as antibacterial agents |
| 08/09/2001 | WO2001056541A1 Cosmetic preparations containing waltheria indica extracts |
| 08/09/2001 | WO2001019814A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 08/09/2001 | WO2001006988A3 Super-active porcine growth hormone releasing hormone analog |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2001003664B1 Stabilized ascorbic acid, composition, and method of use |
| 08/09/2001 | WO2000076452A3 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative |
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000070046A9 Secreted polypeptides and corresponding polynucleotides |
| 08/09/2001 | WO2000067728A3 Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
| 08/09/2001 | WO2000066100A3 2r,4s-hydroxyitraconazole isomers |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000005224A3 Heterocyclic derivatives and their use as integrin inhibitor |
| 08/09/2001 | US20010012895 Therapy for hair loss in mammals; drug resistance; nervous system disorders |
| 08/09/2001 | US20010012856 Compositions and methods for the treatment of anorectal disorders |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | US20010012840 Topical transdermal treatments |
| 08/09/2001 | US20010012837 Anti-ulcer composition |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399274A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 08/09/2001 | CA2399214A1 Novel heterocyclic amide derivatives |
| 08/09/2001 | CA2399083A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | CA2399022A1 Ligand for vascular endothelial growth factor receptor |
| 08/09/2001 | CA2398996A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398678A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr |
| 08/09/2001 | CA2398674A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | CA2398219A1 Dual inhibitors of cholesterol ester and wax ester synthesis for sebaceous gland disorders |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | CA2369050A1 Methods for preventing or attenuating pathoangiogenic conditions |
| 08/08/2001 | EP1121926A1 Cosmetic preparations containing Waltheria indica extracts |
| 08/08/2001 | EP1121444A2 Protein kinase homologs |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121372A1 Adenine derivatives |
| 08/08/2001 | EP1121362A1 Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and antiinflammatory activity |
| 08/08/2001 | EP1121360A1 Il-8 receptor antagonists |
| 08/08/2001 | EP1121359A1 Imidazo-isoquinoline compounds, their compositions and uses |
| 08/08/2001 | EP1121342A1 Diaminopropionic acid derivatives |
| 08/08/2001 | EP1121150A1 Delta 6 fatty acid desaturase |
| 08/08/2001 | EP1121101A1 Aerosol ointment compositions and method of manufacture |
| 08/08/2001 | EP1121096A1 Uv protection compositions |
| 08/08/2001 | EP1121095A1 Uv protection compositions |
| 08/08/2001 | EP1121088A1 Use of nanoscale sterols and sterol esters |
| 08/08/2001 | EP0759740B1 Use of laminarin and oligosaccharides derived therefrom in cosmetics and for preparing a skin treatment drug |
| 08/08/2001 | EP0707486B1 Cutaneous rejuvenating and healing product, method for its manufacture and uses thereof |
| 08/08/2001 | EP0641223B1 Biotherapeutic cell-coated microspheres |
| 08/08/2001 | CN1307637A Polynucleotides isolated from skin cells and methods for their use |
| 08/08/2001 | CN1307590A Treating and diagnosing macrophage-mediated diseases using FC receptor ligands |
| 08/08/2001 | CN1307561A Novel VLA-4 inhibitor: oMePUPA-V |
| 08/08/2001 | CN1307522A Multi-action particle for structuring biological media |
| 08/08/2001 | CN1306845A External-use medicine for treating psoriasis |
| 08/08/2001 | CN1306836A Chinese medicine composition for treating damaged skin |
| 08/08/2001 | CN1306833A External-use extract for treating burns and scalds fast and its preparation |
| 08/08/2001 | CN1306825A Adsorbed burn ointment |
| 08/08/2001 | CN1306823A Ointment for treating dermatosis and its preparation |
| 08/08/2001 | CN1306822A Medicament for treating dermatosis and its preparation |
| 08/08/2001 | CN1306813A Weak ethoxylation dehydrated sorbitol ester composition of washing keratin material |
| 08/08/2001 | CN1069319C Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same |
| 08/08/2001 | CN1069210C Liquid for curing scald and burn and its preparing method |
| 08/08/2001 | CN1069193C Prep. of ointments containing tricyclic compound |
| 08/07/2001 | US6271374 Stable crystalline (6S)- and (6R)-tetrahydrofolic acid |
| 08/07/2001 | US6271268 Treatment of gland disorders with antisecretory agents such as acyl coa cholesterol acyl transferase(acat) inhibitors or prodrugs |
| 08/07/2001 | US6271262 Metalloproteinase inhibitors |
| 08/07/2001 | US6271261 Chemokine mediated diseases, binding interleukins or beta-receptors and administering to mammals |
| 08/07/2001 | US6271248 Substituted biphenysulfonamide endothelin antagonists |
| 08/07/2001 | US6271219 Topical formulations comprising skin penetration agents and the use thereof |
| 08/07/2001 | US6271214 Process for the preparation of immunomodulatory polysaccharides from aloe |
| 08/07/2001 | US6270992 Histidine kinase of Staphylococcus aureus |
| 08/07/2001 | US6270811 Inactive culture of bacteria of the genus bifidobacterium compatible in cosmetics or pharmacy, in a mixture with an essential oil, and an organic acid. |
| 08/07/2001 | US6270791 Soluble keratin peptide |
| 08/07/2001 | US6270752 Based on essential oils obtainable through alcoholic distillation of plants which contain the essential oils, combined with salicylic acid and with fatty acids having 10 to 40 carbon atoms. |
| 08/07/2001 | CA2211006C Topically applied pharmaceutical composition, method of preparing it and its use |
| 08/07/2001 | CA2193520C Use of procysteine as a depigmentation agent |
| 08/07/2001 | CA2121199C Ether derivatives |
| 08/02/2001 | WO2001055692A2 Neurosteroids as markers for alzheimer's disease |
| 08/02/2001 | WO2001055336A2 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055333A2 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055221A1 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 08/02/2001 | WO2001055215A1 Therapeutic peptides |
| 08/02/2001 | WO2001055210A2 Human cyr61 |
| 08/02/2001 | WO2001055149A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid |
| 08/02/2001 | WO2001055147A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS |
| 08/02/2001 | WO2001055134A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 08/02/2001 | WO2001055130A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 08/02/2001 | WO2001055128A1 Formulation for protection against oxidative stress containing benzofuranone derivatives |
| 08/02/2001 | WO2001055115A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | WO2001055114A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 08/02/2001 | WO2001055112A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055092A2 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 08/02/2001 | WO2001054721A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases |